GW Pharma Ends Sativex Licensing Agreement Held With Otsuka Pharmaceutical Co Ltd

The company will now reacquire the complete ownership of the development and commercialization rights to the product’s U.S. market. Reacquisition of these rights will occur without Otsuka receiving any upfront payment.


Go to Source

Powered by WPeMatico